Nanobiotix Advances JNJ-1900 in Recurrent NSCLC
PARIS, France and CAMBRIDGE, Mass. — September 14, 2026 Nanobiotix announced complete Phase 1 safety and efficacy findings for...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
PARIS, France and CAMBRIDGE, Mass. — September 14, 2026 Nanobiotix announced complete Phase 1 safety and efficacy findings for...
RAMAT-GAN, Israel, July 16, 2026 Galmed Pharmaceuticals Ltd. has announced the breakthrough development of a novel lipid nanoparticle (LNP)...
SINGAPORE, May 16, 2026 Researchers at the National University of Singapore have developed a groundbreaking plant-based eye drop technology...
PARIS, France & CAMBRIDGE, USA, April 20, 2026 Nanobiotix has unveiled promising preclinical data demonstrating that its Nanoprimer technology...
PETACH TIKVA, Israel, April 16, 2026 Interna Therapeutics has announced a strategic research collaboration with Daiichi Sankyo to advance...
